SCHEMBL1734290

SCHEMBL1734290

CNC(=O)c1cc(-c2ccccc2)nc(NC)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.65
ADORA1 P30542 11/20 0.53
ADORA3 P0DMS8 4/20 0.53
CHEK1 O14757 1/20 0.50
RET P07949 1/20 0.50
PDGFRB P09619 1/20 0.50
PIM1 P11309 1/20 0.50
PDGFRA P16234 1/20 0.50
GSK3B P49841 1/20 0.50
RPS6KA3 P51812 1/20 0.50
LIMK1 P53667 1/20 0.50
CDK5 Q00535 1/20 0.50
TYRO3 Q06418 1/20 0.50
MAPK14 Q16539 1/20 0.50
LRRK2 Q5S007 1/20 0.50
AURKB Q96GD4 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
DYRK1B Q9Y463 1/20 0.50
ADORA2A P29274 2/20 0.49
ADORA2B P29275 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1733664 0.85 TDP1 (0.65) TDP1ADORA1ADORA3ADORA2AADORA2B
SCHEMBL1734126 0.81 VCP (0.67)
SCHEMBL10051966 0.80 CHEK1 (0.51) TDP1ADORA1ADORA3CHEK1RET
SCHEMBL26523872 0.80 TDP1 (1.00) TDP1ADORA1ADORA3ADORA2AADORA2B
SCHEMBL1735688 0.79 ALDH1A1 (0.53) ADORA1ADORA2AMEN1KMT2ANPC1
SCHEMBL1734465 0.76 KDM4E (0.72) ADORA1ADORA3CHEK1RETPDGFRB
SCHEMBL1939117 0.75 KMO (0.68) ADORA3CHEK1RETPDGFRBPIM1
SCHEMBL1733656 0.74 KDM4E (0.71) CHEK1RETPDGFRBPIM1PDGFRA
SCHEMBL1733509 0.74 KDM4E (0.71) CHEK1RETPDGFRBPIM1PDGFRA
SCHEMBL1734125 0.73 KDM4E (0.45) ADORA1ADORA3CHEK1RETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
EP-1891018-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals, Inc. (US) 2008-02-27 EP claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
WO-2006127588-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-11-30 WO claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 TDP1 3350/4885ADORA1 142/4885ADORA3 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.